Serum Patents (Class 424/531)
-
Patent number: 10213425Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.Type: GrantFiled: October 4, 2017Date of Patent: February 26, 2019Assignee: BESPOKE BIOSCIENCE, LLCInventor: Ivan E. Danhof
-
Patent number: 9950009Abstract: Treatment methods are described using blood collected from a donor after subjecting thereof to remote conditioning such as remote ischemic conditioning via several episodes of short-term limb occlusion. Blood containing remote conditioning substances or a biologically active preparation containing such substances may be stored and used at a future time to afford a health benefit to the treatment subject. Extraction of remote conditioning substances may be done extracorporeally using dialysis or other blood processing methods following by returning of blood to the donor. Extraction of remote conditioning substances may be done during the time periods of their maximum presence in donor blood.Type: GrantFiled: February 13, 2017Date of Patent: April 24, 2018Assignee: LifeCuff Technologies Inc.Inventor: Boris Leschinsky
-
Patent number: 9867820Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.Type: GrantFiled: September 9, 2014Date of Patent: January 16, 2018Assignee: Bespoke Bioscience, LLCInventor: Ivan E. Danhof
-
Patent number: 9687537Abstract: A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH-expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines such as GM-CSF and IFN-?.Type: GrantFiled: July 23, 2010Date of Patent: June 27, 2017Assignee: Rhode Island HospitalInventors: Masafumi Shimoda, Jack R. Wands
-
Publication number: 20150147354Abstract: A method of making a blood product for administration to patient animals to prevent or mitigate a specific condition or disease includes pre-treating one or more donor animals, collecting blood from the donor animals after pre-treatment, and processing the collected blood to make a blood product for administering to one or more patient animals. The pre-treatment step is designed to optimize the levels of one or more components in the blood that play a role in preventing or treating a specific condition or disease.Type: ApplicationFiled: November 26, 2014Publication date: May 28, 2015Applicant: CENTRAL BIOMEDIA, INC.Inventors: TAMMI SUE EPP, JEFFERY SCOTT PENDERGRAFT, DONALD E. MYERS, WILLIAM G. SKELLY
-
Publication number: 20150064164Abstract: The present invention relates to an agent having activity in the treatment of a tissue disruption.Type: ApplicationFiled: September 19, 2014Publication date: March 5, 2015Inventors: Jeffrey D. Edwards, Maud Louise Eijkenboom
-
Publication number: 20150064270Abstract: This invention provides compositions comprising serum protein isolate, whey protein concentrate, and whey protein isolate. The invention also provides methods for increasing lean body mass in a human, comprising administering to the human an effective amount of a composition comprising serum protein isolate and whey protein concentrate.Type: ApplicationFiled: August 7, 2014Publication date: March 5, 2015Inventor: Eric M. Weaver
-
Publication number: 20150032045Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.Type: ApplicationFiled: December 21, 2012Publication date: January 29, 2015Inventors: Rafael Yuste, Roberto Etchenique, Luis Baraldo
-
Patent number: 8932582Abstract: The present invention relates to blood serum and dermally-derived cells for use in tissue repair. Particularly it relates to blood serum and collagen producing cells for use in the treatment of connective tissue injuries. Preferably the cells and the blood serum are autologous and the connective tissue to be repaired is a tendon or ligament. Also provided is a method of treating connective tissue injuries by the administration of blood serum and collagen producing cells directly to the site of injury. It also relates to the use of blood serum and muscle-like cells for use in the treatment of muscle injury, particularly skeletal muscle injury.Type: GrantFiled: November 5, 2009Date of Patent: January 13, 2015Assignee: SportcellInventor: David Connell
-
Publication number: 20140271600Abstract: There is provided a non-cellular bandage and a method of treating damaged tissue derived from a disease or symptom by applying the non-cellular bandage that includes serum, fibrin, and collagen. There is also provided a method of preparing a non-cellular bandage for treating damaged tissue derived from a disease or symptom including the steps of preparing serum, fibrin or an equivalent substitute, and collagen; mixing the serum, the fibrin, and the collagen to form a mixture; and forming a bandage by using the mixture. The non-cellular bandage facilitates the perfect environment in which to actively promote cellular regeneration and tissue repair, while simultaneously reducing immune rejections, scar formation and infection rates when it is applied to a biological tissue.Type: ApplicationFiled: December 13, 2013Publication date: September 18, 2014Inventors: Gabrielle Giet, Ian Milne, Dale Lane
-
Patent number: 8790710Abstract: Cosmetic compositions comprising umbilical cord blood serum and methods of using such compositions to impart anti-aging benefits to the skin are disclosed.Type: GrantFiled: July 14, 2010Date of Patent: July 29, 2014Assignee: Novo Solutions, MD, L.L.C.Inventor: Alvin Needleman
-
Patent number: 8734854Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.Type: GrantFiled: July 9, 2009Date of Patent: May 27, 2014Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
-
Patent number: 8709403Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: November 27, 2012Date of Patent: April 29, 2014Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20140112890Abstract: The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency.Type: ApplicationFiled: April 2, 2012Publication date: April 24, 2014Applicant: The John Hopkins UniversityInventors: Jennifer H. Elisseeff, Iossif Strehin
-
Publication number: 20140105998Abstract: Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an immunogen. Also provided are methods of treatment of certain autommune disorders using such a composition.Type: ApplicationFiled: December 26, 2013Publication date: April 17, 2014Applicant: AIMSCO LimitedInventor: Bryan Youl
-
Publication number: 20140044798Abstract: The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.Type: ApplicationFiled: August 13, 2013Publication date: February 13, 2014Applicant: The Regents of The University of CaliforniaInventors: Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
-
Patent number: 8637005Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: November 14, 2011Date of Patent: January 28, 2014Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20140023720Abstract: Systems and methods for producing enhanced blood serum with concentrated growth factors and/or prophylactically and therapeutically active proteins. An autologous blood product is obtained from a donor and then incubated into a containment device (sterile container) that includes a source of cells or tissue (for example, autologous, allogeneic, or xenographic tissue, or combinations thereof). The cells from the injected fluid (autologous blood product) interact/incubate with the source of cells or tissue inside the containment device, to produce a serum that is loaded with autologous proteins, growth factors, and cytokines. The autologous blood product may be a fluid and/or composition that includes blood, whole blood, autologous conditioned plasma, platelet-rich plasma, platelet-poor plasma, bone marrow aspirate, bone marrow concentrate and stem cells, among others, and combinations thereof.Type: ApplicationFiled: July 15, 2013Publication date: January 23, 2014Inventor: Christopher M. Bare
-
Patent number: 8617893Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.Type: GrantFiled: October 22, 2012Date of Patent: December 31, 2013Assignee: Cambridge Scientific Pty LtdInventors: Jeffrey D. Edwards, John Palermo
-
Publication number: 20130243880Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.Type: ApplicationFiled: September 7, 2012Publication date: September 19, 2013Applicants: THE UNIVERSITY OF TOKUSHIMA, SAISEI MIRAI CLINICInventors: Yoshihiro Uto, Hitoshi Hori, Toshio Inui, Kentaro Kubo
-
Publication number: 20130230600Abstract: Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions.Type: ApplicationFiled: February 8, 2013Publication date: September 5, 2013Applicant: AIMSCO LIMITEDInventors: Angus G. Dalgleish, Martin Cadogan, Jonathan Heeney, Stanley D.T. White
-
Patent number: 8518452Abstract: Process for the stabilization of blood plasma components in a lyophilizate, wherein in a freeze-drying process, said blood plasma components were in a solution containing at least two different pH-lowering substances causing a predetermined pH value range to be adjusted in the solution formed upon reconstitution.Type: GrantFiled: February 15, 2008Date of Patent: August 27, 2013Assignee: Octapharma AGInventors: Kim Bjornstrup, Martin Kern, Andrea Heger, Gerhard Gruber, Hans Sachse, Raimund Schuetz, Juergen Roemisch, Tor-Einar Svae
-
Patent number: 8449922Abstract: A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating normal mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be administered subcutaneously. The effects of the treatment on the individual can be reflected by clinical tests such as hematological immunological profiles and symptom and signs scores.Type: GrantFiled: July 30, 1997Date of Patent: May 28, 2013Inventors: William James Rea, Bertie B. Griffiths
-
Publication number: 20130045279Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.Type: ApplicationFiled: October 22, 2012Publication date: February 21, 2013Applicant: CAMBRIDGE SCIENTIFIC PTY LTDInventor: Cambridge Scientific Pty Ltd
-
Publication number: 20130039991Abstract: The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.Type: ApplicationFiled: June 20, 2012Publication date: February 14, 2013Inventors: Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
-
Patent number: 8343485Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: December 6, 2011Date of Patent: January 1, 2013Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20120315259Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.Type: ApplicationFiled: February 1, 2011Publication date: December 13, 2012Inventor: Hyman Friedlander
-
Publication number: 20120294951Abstract: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Inventors: Graham Joseph Peck, Juliette Peck
-
Patent number: 8303993Abstract: The present relates to an autologous bioadhesive sealant composition, or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting, serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the-platelet rich plasma to form the bioadhesive sealant of the invention.Type: GrantFiled: June 23, 2005Date of Patent: November 6, 2012Assignee: Ateriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Patent number: 8293281Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.Type: GrantFiled: March 31, 2009Date of Patent: October 23, 2012Assignee: Cambridge Scientific Pty LtdInventors: Jeffrey D. Edwards, John Palermo
-
Patent number: 8258117Abstract: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.Type: GrantFiled: October 8, 2010Date of Patent: September 4, 2012Assignee: Piramal Healthcare (Canada) LtdInventors: Caroline D. Hoemann, Michael D. Buschmann, Marc D. McKee
-
Publication number: 20120148601Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: ROBERT G. ULRICH, Mark A. Olson, Sina Bavari
-
Publication number: 20120148569Abstract: An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of Picrorhiza kurrooa Royle, Picrorhiza scrophularflora Pennell and Neopicrorhiza scrophula?iflora. Solvents and solvent combinations are disclosed. The composition is effective against both DNA and RNA viruses and against fungal, bacterial, parasitic and protozoal infections and diseases and also as a hepatoprotective, anti-hyperlipidemic, anti-diabetic and kidney-protective agent. Anti-bodies and vaccines for the cited diseases can be made by administration of the composition to animal or other subjects.Type: ApplicationFiled: September 2, 2010Publication date: June 14, 2012Inventors: Munisekhar Medasani, Satyasayee Babu Divi
-
Publication number: 20120128682Abstract: An isolated human Apolipoprotein L-I corresponding to a wild type human Apolipoprotein sequence is modified by a deletion at its C-terminal end.Type: ApplicationFiled: August 18, 2010Publication date: May 24, 2012Applicant: Universite Libre de BruxellesInventors: Etienne Pays, Laurence Lecordier, Benolt Vanhollebeke
-
Publication number: 20120093936Abstract: The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases and disorders associated with inflammation and/or undesirable activation of the immune system, such as paradentosis, abortus habitualis, colitis ulcerosa, polymyalgia rheumatica, whiplash-associated disorders, endometriosis, adeomyosis and unexplained infertility.Type: ApplicationFiled: April 7, 2010Publication date: April 19, 2012Applicant: VELIN-PHARMA A/SInventors: Svend Lindenberg, Flemming Velin
-
Publication number: 20120045418Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.Type: ApplicationFiled: December 18, 2009Publication date: February 23, 2012Applicant: APOSCIENCE AGInventor: Hendrik Jan Ankersmit
-
Publication number: 20120027867Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: ENTEGRION, INC.Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
Publication number: 20120009248Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.Type: ApplicationFiled: July 29, 2011Publication date: January 12, 2012Applicant: MedImmune, LLCInventors: Vu Truong-Le, Binh Pham
-
Patent number: 8088370Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: March 10, 2009Date of Patent: January 3, 2012Assignee: Amorcyte, Inc.Inventors: Andrew Pecora, Robert Preti
-
Publication number: 20110318424Abstract: The present invention is directed to the use of modulators of the mammalian target of rapamycine (mTOR) pathway, glucose and/or glucose enhancers for treating retinal disorders and, in particular, for prolonging the viability of cone cells.Type: ApplicationFiled: December 3, 2009Publication date: December 29, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Constance Louise Cepko, Claudio Punzo
-
Publication number: 20110244053Abstract: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.Type: ApplicationFiled: June 9, 2011Publication date: October 6, 2011Inventors: Graham Joseph Peck, Juliette Peck
-
Patent number: 8017157Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.Type: GrantFiled: December 12, 2006Date of Patent: September 13, 2011Assignee: Osiris Therapeutics, Inc.Inventors: Won Min Yoo, Kyung Hee Chang, Nae Choon Yoo, Ki Chang Keum, Sang Yup Lee, Gene Lee
-
Publication number: 20110177015Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves putting mesenchymal stem cells or other cells with regenerative properties into culture medium to induce secretion of beneficial factors such as growth factor, regulatory factors, enzymes, hormones, peptides and lymphokines into the culture medium to create conditioned medium and then extracting either a supernatant or a cell free extract of the conditioned medium to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.Type: ApplicationFiled: October 11, 2009Publication date: July 21, 2011Inventor: Hymie Friedlander
-
Publication number: 20110177036Abstract: The present invention relates to a whole-blood culture containing specific immunocompetent killer cells that are activated against tumor cells, viruses, bacteria and/or allergens, whereby the whole-blood culture consists of whole-blood and a culture medium at a ratio of 3:1 to 4:1, whereby the culture medium has an oxygen excess of at least 100% or more and contains a water-soluble emulsification product comprising a mixture of phospholipids, vitamin E, and low-molecular proteoglycans with a molecular weight of 1,200 to 12,000 Dalton, and whereby dead tumor cells or fragments thereof and/or viral and/or bacterial antigens and/or allergens have been added to the whole-blood culture [to serve] as antigen in the specific recognition process for production of the activated killer cells (stimulation). The invention also relates to a method for producing the culture, as well as stimulants for the whole-blood culture and a method for the selection thereof.Type: ApplicationFiled: January 31, 2011Publication date: July 21, 2011Inventors: Horst KIEF, Thorsten Kief
-
Publication number: 20110086046Abstract: A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal.Type: ApplicationFiled: January 28, 2003Publication date: April 14, 2011Inventors: Jonathan Heeney, Angus G. Dalgleish, Stanley D.T. White
-
Patent number: 7906149Abstract: A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.Type: GrantFiled: May 25, 2007Date of Patent: March 15, 2011Assignee: Boval Company, L.P.Inventor: Cody L. Yarborough
-
Patent number: 7858087Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.Type: GrantFiled: July 25, 2007Date of Patent: December 28, 2010Assignee: University of Virginia Patent FoundationInventors: Ronald P. Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam Kennedy
-
Publication number: 20100323029Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
-
Patent number: 7838039Abstract: Provided are methods of applying biological compositions, that is, autologous bioadhesive sealant compositions containing one or more biological agents, to an individual, wherein all the blood components used in preparing the composition are derived from the patient who is to receive the biological composition. In one embodiment, the method comprises obtaining a whole blood sample from an individual; forming an inactive platelet rich plasma from the whole blood sample; mixing a biological agent into the inactive platelet rich plasma; obtaining thrombin from the whole blood sample; mixing the thrombin into the inactive platelet rich plasma to form a biological composition; and applying the biological composition to the individual.Type: GrantFiled: January 27, 2005Date of Patent: November 23, 2010Assignee: Arteriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera